GBM AGILE is an entirely unique approach to clinical trials made possible by the partnership and collaboration of clinicians, scientists, pharmaceutical/biotech companies, regulators, patient advocacy groups and patients.
ADVOCACY PARTNERS
STRATEGIC PARTNERS
DESIGN PHASE SUPPORT
Thank you to our advocacy partners, who played a major role in funding the development of GBM AGILE:
Asian Fund for Cancer Research
Cure Brain Cancer Foundation
National Biomarker Development Alliance
National Brain Tumor Society
National Foundation for Cancer Research
Building on previous biomedical research discoveries, including traditional randomized controlled trials, a committed group of over 130 oncologists, statisticians, pathologists, neurosurgeons, imaging experts, advocates, and researchers from academia, industry, and government worked collectively founding the design of a new type of clinical trial in 2015 – GBM AGILE – that will further enhance the way therapies are identified for this deadly disease. This remarkable “GBM Knowledge Network” of global experts, led by the GBM AGILE Executive Committee, met regularly as collaborative teams to shape the adaptive design and master protocol for GBM AGILE.
ADDITIONAL COLLABORATORS
